Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot

• The compliance to treatment with Lucrin Depot in patients with endometriosis [ Time Frame: For a duration of 6 months of observation ] [ Designated as safety issue: No ]
• Adverse events for estrogen deficiency symptoms [ Time Frame: For a duration of 6 months of observation ] [ Designated as safety issue: Yes ]

400 eligible patients with endometriosis will be enrolled at 38 sites in Russia. Study medication will be administered by injection once a month. Planned duration of therapy 6 months. The rates of administration of hormone add-back therapy or non-hormone add-back therapy to reduce estrogen deficiency symptom, planned for a 6-month course of gonadoliberin agonist Lucrin Depot in patients with endometriosis will be described.

400 eligible patients with genital endometriosis will be enrolled at 38 sites in Russia. Study medication Lucrin Depot will be administered at a dose of 3.75 mg by intramuscular or subcutaneous injection once a month. The first injection will be carried out on the 3rd day of menstrual period. Planned duration of therapy 6 months. The rates of administration of hormone add-back therapy or non-hormone add-back therapy to reduce estrogen deficiency symptom, planned for a 6-month course of gonadoliberin agonist Lucrin Depot in patients with endometriosis will be described.

Primary care clinic

Inclusion Criteria

• Age from 18 to 50 years
• Written Patient Consent for Use/Disclosure of Data
• Diagnosis of genital endometriosis confirmed by Laparoscopy(external genital endometriosis) or Ultrasound(internal genital endometriosis)
• Candidate for treatment with Lucrin Depot for 6-month course
• Patients with suspected endometriosis suffering from chronic pelvic pain if another reasons of pain are excluded

Exclusion Criteria

• Contraindications to administration of Lucrin Depot (Leuprorelin):

  • Hypersensitivity to Leuprorelin similar products of protein origin or any of the excipients in drug product composition
  • Vaginal bleedings of unknown etiology
  • Surgical castration
  • Pregnancy and lactation
• Menopause(absence of cyclic menstrual hemorrhages for 1 year before the start of this program)
• Acute infectious period, inclusive of acute inflammatory diseases of small pelvic organs
• Other contraindications, that make the patients participation impossible (by investigator judgment)
• Previous enrollment in the present program
• Extragenital endometriosis